Trial Holdings Aktie
WKN DE: A3D8YD / ISIN: JP3635490000
28.09.2025 16:15:00
|
Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?
Over the past five years, Eli Lilly (NYSE: LLY) has outperformed the broader market, largely thanks to its progress in the GLP-1 arena. Its major breakthroughs in the field are already leading to incredible commercial success.But Lilly isn't done just yet. Recent clinical developments may set the stage for further stock-market gains, and potentially allow the drugmaker to maintain that momentum through the end of the decade. Let's find out what Eli Lilly has been up to, and what that means for investors.Eli Lilly's tirzepatide, marketed under the brands Mounjaro for diabetes and Zepbound for weight management, is highly effective -- and generating billions of dollars in sales per quarter already. However, the medicine is administered subcutaneously once a week. This route has several drawbacks compared to oral pills.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Trial Holdings Inc. Registered Shsmehr Nachrichten
Analysen zu Trial Holdings Inc. Registered Shsmehr Analysen
Aktien in diesem Artikel
Trial Holdings Inc. Registered Shs | 2 376,00 | 0,51% |
|